Highlights

• Ansell grew FY26 sales 6.8 per cent to US$2,140.2 million, with adjusted EBIT rising to US$321.9 million.

• Adjusted EBIT margin widened to 15.0 per cent from 14.1 per cent, with Healthcare margin reaching 14.3 per cent.

• Ansell declared a final dividend of 41.50 US cents, taking the FY26 total to 68.10 US cents per share.

• Ansell guided FY27 adjusted EPS to between US158 cents and US170 cents, before the effects of its buyback.

A wider margin, a stronger cash flow and a defined earnings range for the year ahead anchor the FY26 result at Ansell Limited (ASX:ANN). Shares were trading at A$46.27 on 23 October 2026, up 1.11%.

Margins Widen as Sales Grow

Ansell reports in US dollars. Sales for the year ended 30 June 2026 reached US$2,140.2 million, up 6.8 per cent as reported and 5.0 per cent on an organic constant currency basis. Adjusted EBIT rose 14.1 per cent to US$321.9 million, lifting the margin to 15.0 per cent from 14.1 per cent.

Profit attributable to shareholders more than doubled, up 105.3 per cent to US$208.6 million, partly because significant items shrank to a net charge of US$1.4 million from US$98.2 million a year earlier. Adjusted earnings per share climbed 17.8 per cent to 148.6 US cents.

Healthcare Leads, Industrial Holds Its Margin Edge

The Healthcare segment recorded sales of US$1,192.9 million, up 8.0 per cent, and adjusted EBIT of US$170.7 million, up 20.3 per cent. Its margin improved to 14.3 per cent from 12.8 per cent. Cleanroom sales grew 10.0 per cent on an adjusted basis, and management cited growth from cleanroom, surgical and examination and single-use products.

Industrial sales rose 5.4 per cent to US$947.3 million, with adjusted EBIT of US$170.6 million and an 18.0 per cent margin, up from 17.3 per cent. Mechanical sales grew 6.5 per cent, while chemical sales edged up 0.5 per cent. Aerospace and defence contributed to growth in the segment.

Cash Flow, Balance Sheet and Dividends

Operating cash flow rose to US$388.6 million from US$239.3 million. Net debt fell to US$510.6 million from US$570.2 million, bringing net debt to adjusted EBITDA to 1.3 times from 1.6 times. Cash and undrawn facilities totalled US$752.4 million.

Ansell completed about US$118 million of a US$200 million on-market share buyback during the year, funded from operating cash flow, and the program is continuing.

Tariffs featured in the year. Management said the impact of United States tariffs was offset through sourcing changes and price increases. The year's results included US$12.1 million of tariff refund receivables, and about US$12 million was received in July.

The board declared an unfranked final dividend of 41.50 US cents per share, paid on 17 September 2026 to holders on the 1 September record date. The full-year dividend reached 68.10 US cents, compared with 50.20 US cents in FY25. The dividend is sourced from the Conduit Foreign Income Account, so non-resident shareholders should not face withholding tax.

FY27 Guidance and Priorities

Ansell expects FY27 adjusted earnings per share of between US158 cents and US170 cents, before significant items and excluding the effect of the on-market buyback. It anticipates constant currency sales growth from higher volumes and from pricing actions completed in FY26, with priority on the United States, scientific and select industrial markets.

Other planning assumptions include capital expenditure of US$45 million to US$55 million, net interest cost of about US$43 million and a book tax rate of 23.5 to 24.5 per cent. Significant items of about US$15 million before tax are forecast, mainly for ERP implementation.

The company's three strategic priorities are commercial excellence, a focus on strategic markets and operational excellence. Its annual general meeting is scheduled for 9 November 2026.